8-K: Moleculin Partners with UNC for Pancreatic Cancer Research

Moleculin Biotech, Inc. announced a research agreement with the University of North Carolina at Chapel Hill to evaluate Annamycin for pancreatic cancer treatment.

Summary

• Moleculin Biotech, Inc. has entered into a research and material transfer agreement with the University of North Carolina at Chapel Hill (UNC) for investigator-initiated preclinical research.
• The research will evaluate Annamycin for the treatment of pancreatic cancer, a highly lethal and underserved cancer.
• Moleculin will supply Annamycin, and Dr. William C. Zamboni at UNC will conduct the preclinical studies as part of a series of funded grants.
• The studies will assess novel treatment agents and modalities to enhance tumor delivery of liposomal Annamycin (L-Annamycin) and Free-Annamycin compared to Doxil and Free-doxorubicin in PDAC GEMM models.
• Annamycin has demonstrated a high affinity for and ability to concentrate in the pancreas, and its primary target, topoisomerase II, is highly correlated with poor survival in pancreatic cancer patients.
• Annamycin currently holds Fast Track Status and Orphan Drug Designation from the FDA for relapsed or refractory AML and STS lung metastases, and Orphan Drug Designation from the EMA for relapsed or refractory AML.
• Moleculin is also conducting the pivotal Phase 3 MIRACLE trial (MB-108) for Annamycin in combination with cytarabine (AnnAraC) for the treatment of relapsed or refractory acute myeloid leukemia (AML).

Sentiment

Score: 7

Explanation: The announcement of a new research collaboration with a reputable institution like UNC for a high-need indication (pancreatic cancer) is a positive development for Moleculin's pipeline expansion. However, the explicit mention of needing significant additional financing without commitments introduces a notable risk factor.

Positives

• Collaboration with a leading institution, the University of North Carolina at Chapel Hill, known for oncology innovation and translational research.
• Expansion of Annamycin's potential clinical applications into pancreatic cancer, an indication with significant unmet medical need and market potential.
• Annamycin has demonstrated high affinity for and ability to concentrate in the pancreas, which is a key factor for treating pancreatic cancer.
• Preclinical studies indicate Annamycin targets topoisomerase II, which is highly correlated with poor survival in pancreatic cancer patients.
• The research is supported by a series of funded grants, indicating external validation and financial support for the studies.
• Annamycin already possesses Fast Track Status and Orphan Drug Designations from regulatory bodies for other difficult-to-treat cancers (AML, STS lung mets).

Risks

• Moleculin will require significant additional financing to conduct its clinical trials as described in the press release.
• The company currently has no commitments for the necessary additional financing.
• The achievement of described milestones is contingent on the company's ability to secure such financing on a timely basis.
• Forward-looking statements involve known and unknown risks, uncertainties, and other factors, and expectations may prove to be materially different from actual results.

Future Outlook

The company aims to advance and develop Annamycin through multiple investigator-initiated studies to realize its full potential, specifically targeting pancreatic cancer in addition to acute myeloid leukemia and soft tissue sarcoma. They anticipate generating data that will help define Annamycin's role in pancreatic cancer and further strengthen their oncology development pipeline. The company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for AML, subject to appropriate future filings and potential additional feedback from regulatory bodies.

Management Comments

• "We are pleased to establish this agreement with the team at UNC-Chapel Hill, a leading institution in oncology innovation and translational research, and take another important step in our strategy to advance and develop Annamycin through multiple investigator-initiated studies to realize its full potential." Walter Klemp, Chairman and CEO of Moleculin.
• "Pancreatic cancer remains one of the most lethal and underserved cancers, with limited effective treatment options and a clear need for new therapeutic approaches." Walter Klemp.
• "Evaluating Annamycin in collaboration with UNCs world-class translational scientists dovetails well with our recently announced investigator-funded clinical trial in pancreatic cancer patients." Walter Klemp.
• "Annamycin has a demonstrated high affinity for and ability to concentrate in the pancreas, and recently published data reveals that the upregulation of topoisomerase II, the primary target of Annamycin, is highly correlated with poor survival in pancreatic cancer patients." Walter Klemp.
• "This is why we believe targeting pancreatic cancer in addition to acute myeloid leukemia and soft tissue sarcoma provides a critical strategic opportunity to expand the potential clinical applications of our technology into an indication with significant unmet need and market potential." Walter Klemp.
• "We look forward to generating data that will help define Annamycins role in pancreatic cancer and further strengthen our oncology development pipeline as we work to deliver meaningful value for patients and shareholders." Walter Klemp.

Industry Context

Pancreatic cancer is recognized as one of the most lethal and underserved cancers, characterized by limited effective treatment options and a significant unmet medical need. This collaboration positions Moleculin to potentially address this critical area, aligning with broader industry trends focused on developing novel therapies for difficult-to-treat cancers. The strategy of utilizing investigator-initiated studies and partnering with prominent academic institutions like UNC is a common and effective approach in pharmaceutical development to expand research and clinical applications for drug candidates.

Stakeholder Impact

• Shareholders: Potential for increased long-term value through pipeline expansion into a high-need market, but also risk from the explicit need for additional financing and potential dilution.
• Patients: Potential for new, more effective treatment options for pancreatic cancer, a highly lethal disease with limited existing therapies.
• Researchers/Medical Community: Collaboration with UNC could lead to new scientific insights and advancements in cancer treatment, fostering further research and development.

Next Steps

• Conduct investigator-initiated preclinical research evaluating Annamycin for pancreatic cancer at UNC-Chapel Hill.
• Evaluate the ability of novel treatment agents and modalities to enhance tumor delivery of liposomal Annamycin and Free-Annamycin.
• Generate data that will help define Annamycin's role in pancreatic cancer.
• Continue the pivotal Phase 3 MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia (AML).

Key Dates

Recommendation

While the collaboration with UNC for pancreatic cancer research is a positive strategic move, expanding Annamycin's potential applications into a high-unmet-need area, the early preclinical stage of this specific research and the explicit disclosure of a significant need for additional financing without commitments introduce considerable uncertainty and potential for dilution. Investors should hold to monitor progress in both the pancreatic cancer research and the ongoing AML trial, as well as the company's ability to secure necessary funding.

Keywords

Moleculin Biotech, MBRX, Annamycin, Pancreatic Cancer, Oncology, Preclinical Research, UNC-Chapel Hill, Drug Development, Cancer Treatment, Biotech, AML, STS